Rotenone

别名: Barbasco, Dactinol, Paraderil, Rotenon, Rotocide 中文名称：鱼藤酮

目录号：S2348 Purity: 99.97%

Rotenone是一种植物杀虫剂，是线粒体电子传递mitochondrial electron transport的抑制剂。Rotenone 可抑制 NADH/DB oxidoreductase 和 NADH oxidase，对应的IC50值分别为28.8 nM和5.1 nM。Rotenone 可通过增强线粒体活性氧的产生来诱导凋亡。Rotenone 可用于诱导帕金森病动物模型。

Rotenone Chemical Structure

CAS: 83-79-4

规格	价格	库存
25mg	794.7	现货
1g	3030.98	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.97%

99.97

Rotenone相关产品

相关靶点	NOX1 NOX4 NOX2	点击展开
相关产品	Setanaxib (GKT137831) DPI (Diphenyleneiodonium chloride) 2-Acetylphenothiazine (ML171) VAS2870 GLX351322 GSK2795039	点击展开
相关化合物库	激酶抑制剂库 FDA药物库天然产物库已知活性药物库-I 高选择性抑制剂库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息(PMID)
MG63	Function assay	1 uM	1 hr	Increase in lactate production in MG63 cells at 1 uM after 1 hr by ELISA	17088489
N548	Activation of AKT in	10 uM	6 hrs	Activation of AKT in DNA-deficient rat striatal neuronal N548 mutant cells at 10 uM after 6 hrs by Western blotting	17726098
N548	Cell death rescue assay	10 uM	7 days	Cell death rescue in rat striatal neuronal N548 mutant cells analysed every day for 7 days at 10 uM by trypan blue dye-exclusion assay	17726098
T47D	Function assay	0.01 to 0.1 uM	72 hrs	Reduction in ATP level in human T47D cells at 0.01 to 0.1 uM after 72 hrs by HPLC-UV analysis	21875114
T47D	Function assay	0.1 to 1 uM	30 mins	Inhibition of mTOR in human T47D cells assessed as eIF2alpha hyperphosphorylation on Ser 51 at 0.1 to 1 uM after 30 mins by Western blotting	21875114
T47D	Function assay	0.1 to 1 uM	30 mins	Inhibition of mTOR in human T47D cells assessed as eEF2 hyperphosphorylation on Ser 56 at 0.1 to 1 uM after 30 mins by Western blotting	21875114
MDA-MB-231	Function assay	0.1 to 1 uM	30 mins	Inhibition of mTOR in human MDA-MB-231 cells assessed as eIF2alpha hyperphosphorylation on Ser 51 at 0.1 to 1 uM after 30 mins by Western blotting	21875114
MDA-MB-231	Function assay	0.1 to 1 uM	30 mins	Inhibition of mTOR in human MDA-MB-231 cells assessed as eEF2 hyperphosphorylation on Ser 56 at 0.1 to 1 uM after 30 mins by Western blotting	21875114
MDA-MB-231	Function assay	0.01 to 0.1 uM	48 hrs	Reduction in ATP level in human MDA-MB-231 cells at 0.01 to 0.1 uM after 48 hrs by HPLC-UV analysis	21875114
N548	Activation of ERK in	10 uM		Activation of ERK in rat striatal neuronal N548 mutant cells at 10 uM by Western blotting	17726098
N548	Activation of AKT in	10 uM		Activation of AKT in rat striatal neuronal N548 mutant cells at 10 uM by Western blotting	17726098
N548	Activation of ERK in	50 uM		Activation of ERK in rat striatal neuronal N548 mutant cells at 50 uM by Western blotting	17726098
N548	Activation of AKT in	50 uM		Activation of AKT in rat striatal neuronal N548 mutant cells at 50 uM by Western blotting	17726098
N548	Cell death rescue assay	10 uM		Cell death rescue in DNA-deficient rat striatal neuronal N548 mutant cells at 10 uM	17726098
T47D	Function assay	0.001 to 0.1 uM		Inhibition of cellular respiration in human T47D cells assessed as rate of oxygen consumption at 0.001 to 0.1 uM	21875114
TA3/Ha	Function assay	12 uM		Induction of NAD(P)H oxidation in mouse TA3/Ha cells assessed as reduction of NAD(P)H/NAD(P)+ ratio at 12 uM by spectrofluorometer analysis	24568614
U937	Antiproliferative assay		72 hrs	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay, IC50=0.07μM	17158054
U937	Antiproliferative assay		48 hrs	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay, IC50=0.2μM	17158054
U937	Antiproliferative assay		24 hrs	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay, IC50=13μM	17158054
HepG2	Antitumor assay		24 hrs	Antitumor activity against human HepG2 cells after 24 hrs by MTT assay, ED50=15μM	17482824
A549	Antitumor assay		24 hrs	Antitumor activity against human A549 cells after 24 hrs by MTT assay, ED50=26μM	17482824
U373 MG	Antiproliferative assay		72 hrs	Antiproliferative activity against human U373 MG cells after 72 hrs	18513974
T47D	Function assay		48 hrs	Reduction in ATP level in human T47D cells after 48 hrs by HPLC-UV analysis	21875114
697	Cytotoxicity assay		72 hrs	Cytotoxicity against human 697 cells after 72 hrs by MTS assay, IC50=0.3μM	23895019
697	Cytotoxicity assay		48 hrs	Cytotoxicity against human 697 cells after 48 hrs by MTS assay, IC50=0.3μM	23895019
HT-29	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay, IC50=0.3μM	23895019
Raji	Cytotoxicity assay		72 hrs	Cytotoxicity against human Raji cells after 72 hrs by MTS assay, IC50=1.1μM	23895019
Raji	Cytotoxicity assay		48 hrs	Cytotoxicity against human Raji cells after 48 hrs by MTS assay, IC50=4.2μM	23895019
HepG2	Cytotoxicity assay		24 hrs	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay, IC50=1.52μM	30613327
HEK293	Function assay			Effect on cofilin1 expressed in HEK293 cells assessed as effect on cofilin1; Limk2 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	16680159
HEK293	Function assay			Inhibition of of c-Jun expressed in HEK293 cells assessed as induction of protein interaction in presence of camptothecin with Pin1 by EYFP based reporter gene assay	16680159
HEK293	Function assay			Effect on p53 expressed in HEK293 cells assessed as effect on p53-p53 interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	16680159
HEK293	Function assay			Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25A interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	16680159
HEK293	Function assay			Effect on Cdc2 expressed in HEK293 cells assessed as effect on Cdc2:Cdc25C interaction complexes in presence of camptothecin by EYFP and/or YFP Venus fragment based reporter gene assay	16680159
HT1080	Function assay			Inhibition of proMMP2 production in human HT1080 cells by gelatin zymography analysis	17158054
HT1080	Function assay			Inhibition of proMMP9 production in human HT1080 cells by gelatin zymography analysis	17158054
neural precursor cells	Function assay			Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	17417631
N548	Cell death rescue assay			Cell death rescue in rat striatal neuron N548 mutant cells, EC50=0.5μM	17726098
ASH neuronal cells	Cell death rescue assay			Cell death rescue of ASH neuronal cells in Caenorhabditis elegans Huntington's disease model, EC50=2μM	17726098
neuronal cells	Cell death rescue assay			Cell death rescue of neuronal cells in drosophila Huntington's disease model, EC50=10μM	17726098
N548	Toxicity assay			Toxicity in rat striatal neuronal N548 mutant cells, TC50=40μM	17726098
N548	Cell death rescue assay			Suppression of cell death in rat striatal neuronal N548 mutant cells assessed as suppression of caspase 7 activation by Western blotting	17726098
N548	Cell death rescue assay			Cell death rescue in rat striatal neuronal N548 mutant cells by calcein acetoxymethyl ester assay	17726098
N548	Cell death rescue assay			Suppression of cell death in rat striatal neuronal N548 mutant cells assessed as suppression of caspase 3 activation by Western blotting	17726098
Hepa-1c1c7	Cytotoxicity assay			Cytotoxicity against mouse Hepa-1c1c7 cells, IC50=0.7μM	23895019
Hepa1c1c7	Function assay			Induction of quinone reductase in mouse Hepa1c1c7 cells, CD=0.8μM	23895019
L5178Y	Cytotoxicity assay			Cytotoxicity against mouse L5178Y cells by MTT assay, IC50=0.3μM	28075580
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	29435139
fibroblast cells	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	29435139
DLD1	Function assay			Inhibition of mitochondrial oxidative phosphorylation in human DLD1 cells assessed as reduction in oxygen consumption rate by seahorse XFe96 analyser based assay	31774672
点击查看更多细胞系数据

生物活性

产品描述	Rotenone是一种植物杀虫剂，是线粒体电子传递mitochondrial electron transport的抑制剂。Rotenone 可抑制 NADH/DB oxidoreductase 和 NADH oxidase，对应的IC50值分别为28.8 nM和5.1 nM。Rotenone 可通过增强线粒体活性氧的产生来诱导凋亡。Rotenone 可用于诱导帕金森病动物模型。

参考文献
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641941/ https://pubmed.ncbi.nlm.nih.gov/34531546/

参考文献

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641941/
https://pubmed.ncbi.nlm.nih.gov/34531546/

化学信息&溶解度

分子量	394.42	分子式	C₂₃H₂₂O₆
CAS号	83-79-4	SDF	Download Rotenone SDF
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 40 mg/mL ( (101.41 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 55 mg/mL ( (139.44 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 2 mg/mL (5.07 mM)

Water : Insoluble

DMSO : 79 mg/mL ( (200.29 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

DMSO : 79 mg/mL ( (200.29 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Water : Insoluble

Ethanol : Insoluble

摩尔浓度计算器

体内溶解配方批次：现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂				动物体内配方计算器
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
澄清溶液	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O 该配方已经过Selleck实验室实测。如果上述溶解方案不能满足您的需求，可联系Selleck销售提供定制化测试。	3.900mg/ml (9.89mM)	以 1 mL 工作液为例,取50μL78mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
澄清溶液	5% DMSO 1 95% Corn oil 该配方已经过Selleck实验室实测。如果上述溶解方案不能满足您的需求，可联系Selleck销售提供定制化测试。	0.980mg/ml (2.48mM)	以1 mL工作液为例，取50μL 19.6mg/ml的澄清DMSO储备液加到950μL玉米油中，混合均匀。工作液请现配现用！
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):